-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse NYSE New York Stock ExchangeUSDISIN US7170811035-
PfizerBörse NYSE New York Stock ExchangeISIN US7170811035 WKN: 852009USDSymbol PFE
-
PfizerBörse Börse StuttgartISIN US717081DK61EURSymbol PFE
-
PfizerBörse Xetra FrankfurtISIN US717081ER06EURSymbol PFE
-
PFIZER INCBörse Börse HamburgISIN US717081ED10EURSymbol PFE
-
PFIZER INCBörse Börse DüsseldorfISIN XS1574158082EURSymbol PFE
-
PFIZER INCBörse Börse MünchenISIN US717081DZ31EURSymbol PFE
-
PFIZER INCBörse Gettex System der Börse MünchenISIN US717081ES88EURSymbol PFE
-
PFIZER INCBörse Tradegate System der Deutsche Börse AG (60%)ISIN US717081EQ23EURSymbol PFE
-
PFIZER INCBörse Quotrix System der Börse DüsseldorfISIN US717081DE02EURSymbol PFE
-
PFIZER INCBörse Börse FrankfurtISIN XS1574157357EURSymbol PFE
-
PfizerBörse Xetra FrankfurtEURISIN US717081EY56
-
PfizerBörse Börse MünchenEURISIN US717081FA61
-
PfizerBörse SSE Stockholm Stock ExchangeISIN US717081EZ22SEKSymbol PFE
-
PfizerBörse Bolsa Mexicana de Valore Mexiko-StadtISIN US717081EK52MXNSymbol PFE
-
PfizerBörse Bolsa de Comercio de Buenos AiresUSDISIN US717081DV27
-
PfizerBörse Bolsa Mexicana de Valore Mexiko-StadtMXNISIN US717081DH33
-
PfizerBörse BUEUSDISIN US717081EV18
-
ISIN US717081EX73EURSymbol PFE
-
PfizerBörse OMXSSEKISIN US7170811035
-
EURISIN US717081EJ89
-
PFIZER INCBörse SSEISIN US717081EP40
-
ISIN US7170811035
WKN 852009
Symbol PFE
Währung
USD
Börse
NYSE New York Stock Exchange Zeitzone: Europe/Berlin
Firmenname
Pfizer IncCEO: Albert Bourla
Marktkapitalisierung
210.568.636.569 (+- 19%)
Die einen sagen so, die anderen so... Es gibt 4 Datenquellen:
204.882.624.512 oder 249.774.306.515 oder 216.419.000.000 oder 171.198.615.249
Mitarbeiter
85.667 (+- 5%)
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
88.300 oder 90.200 oder 78.500 Mitarbeiter
Anzahl Aktien
5.558.396.599
KGV
18.68 (+- 28%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
23.97 oder 13.4
EBITDA 19.320.000.512
PEGRatio 4.9741
Buchwert 11.744
Zahlte zuletzt am 06.05.2021 eine Dividende von 0,39 USD . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 4,02 % p. a.
beim aktuellen Kurs von 36,59 USD -0,04%
Pfizer underperformed den DAX um -10 % (+35 % Dividenden) vom 30.09.2013 bis 14.09.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 36,59 USD -0,04%
Letzte Communitymeinungen
- 2 User waren zuletzt bullisch
- Im Alpha-Tester Battle 2021
-
casixxx
-
Harry386
Ein User hat Pfizer abonniert.
Aktionärsstruktur der Pfizer Inc
Portrait der Pfizer Aktie
Das Unternehmen Pfizer Inc aus USA beschäftigt 85.667 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie, Pharma tätig.
Tochterunternehmen von Pfizer sind: Pfizer Ltd/India, PFIZER LTD., Pfizer Limited.
Die Pfizer Aktie hat inklusive der Dividendenausschüttungen seit dem 30.09.2013 eine Gesamtrendite von 108% erwirtschaftet
Das Unternehmen Pfizer Inc ist in mehr als 90 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter VanEck Vectors Morningstar Durable Dividend ETF gewichtet Pfizer mit 5,94% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Pfizer Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Pfizer Inc am höchsten gewichtet ist Insgesamt in 90 ETFs enthalten
Dir gefallen die Informationen zu Pfizer?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Pfizer?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Pfizer?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Pfizer?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
938 News & Informationen zur Pfizer Aktie
U.S. administers nearly 349 million doses of COVID-19 vaccines
U.S. administers nearly 349 million doses of COVID-19 vaccines – CDC
Moderna recommends covid-19 vaccine booster to protect against new variants
Company said vaccine sales rose above $4 billion in the latest quarter and that it signed $20 billion worth of advanced purchase agreements for 2021
Moderna claims its COVID-19 vaccine remains 93% effective 4-6 months after second dose
Moderna's vaccine was authorized for emergency use in adults in the United States in December and has since been cleared for emergency or conditional use in adults in more than 50 countries
Moderna : says its COVID-19 shot maintains high efficacy through 6 months
Moderna Inc said on Thursday its COVID-19 vaccine was about 93% effective through six months after the second dose, showing hardly any change from the 94% efficacy reported in its original… | August 5, 2021
Global Depression Treatment Market (2020 to 2026) – Featuring Allergen, Bausch Health Companies and Lief Therapeutics Among Others
/PRNewswire/ — The
Global Depression Treatment Market (2020 To 2026) – Featuring Allergen, Bausch Health Companies And Lief Therapeutics Among Others
DUBLIN, Aug. 5, 2021 /PRNewswire/ — The
Why Delta Is Making Herd Immunity Harder to Reach
Many countries are counting on vaccines to build sufficient immunity in their populations so that SARS-CoV-2, the virus that causes Covid-19, isn’t able to find enough people to infect, causing transmission to eventually stop. But even in countries with a high proportion of people inoculated with highly effective vaccines, it’s unclear whether it’s possible to reach the so-called herd immunity threshold anytime soon. Researchers warn that the virus is apt to be circulating among us for a long ti
Global Cancer Therapies Market to Reach $204.2 Billion by 2024
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Moderna Covid vaccine tallies more than $4B in Q2 sales
The company also said Thursday an analysis showed that its vaccine remains 93 per cent effective as much as six months after the second dose
U.S. COVID-19 cases hit six-month high, Florida grapples with surge By Reuters
U.S. COVID-19 cases hit six-month high, Florida grapples with surge
Moderna CEO On Q2 Earnings And Vaccine Efficacy Data
Following is the unofficial transcript of a CNBC interview with Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel on CNBC’s “Squawk Box”
What Really Mattered With Pfizer's Q2 Results
It's more about what's on the way than what happened in the second quarter.
Moderna says its covid vaccine remains 93% effective 6 months after second dose
'We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through six months, but recognize that the Delta variant is a significant new threat so we must remain vigilant,' said Stéphane Bancel, Chief Executive Officer of Moderna
Moderna says its COVID-19 shot remains 93% effective 4-6 months after second dose
Moderna posted second-quarter sales of $4.4 billion, slightly above an average estimate of $4.2 billion drawn from 10 analysts polled by Refinitiv. Its COVID-19 shot is the firm's first authorized product and sales were just $67 million in the same period last year.
Moderna says its COVID-19 shot remains 93% effective 4-6 months after second dose By Reuters
Moderna says its COVID-19 shot remains 93% effective 4-6 months after second dose
Antares Pharma Reports Second Quarter 2021 Financial and Operating Results
Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J.,…
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Projecting over $33 billion in COVID-19 vaccine revenue alone in 2021, CEO Albert Bourla wants to beef up Pfizer's pipeline.
Is BioNTech Contradicting Pfizer About the Need for Booster Doses?
It might seem to be the case, at least at first glance.
Pfizer to require COVID vaccinations for all U.S. employees (NYSE:PFE)
Pfizer (PFE) with its German partner BioNTech (BNTX) said that it will require all its U.S
This Cheap Stock Opens up a $100 Billion Medical Market
The coronavirus vaccine grabbed the most headlines this year, but other advances in science could mean a big boost for this one cheap stock…
Why Delta Is Shifting the Herd Immunity Goal Posts
(Bloomberg) — Many countries are counting on vaccines to build sufficient immunity in their populations so that SARS-CoV-2, the virus that causes Covid-19, isn’t able to find enough people to infect, causing transmission to eventually stop.
Kahn Brothers Buys Pfizer Inc, Organon, JPMorgan Chase, Sells Nam Tai Property Inc, BlackBerry
GuruFocus Article or News written by insider and the topic is about:
Factbox: Major U.S. companies making masks, vaccines mandatory By Reuters
Factbox: Major U.S. companies making masks, vaccines mandatory
U.S. administers 348.1 million doses of COVID-19 vaccines
U.S. administers 348.1 million doses of COVID-19 vaccines – CDC
Pfizer to require U.S. workers receive COVID-19 vaccine or regular tests By Reuters
Pfizer to require U.S. workers receive COVID-19 vaccine or regular tests
3 COVID Stocks That Could Soar Higher
Here's why Pfizer, Inari Medical, and Novavax shares might be more valuable in 2021.
Pfizer – Wind Beneath its Wings
GuruFocus Article or News written by Praveen Chawla and the topic is about: The Covid-19 vaccine is powering the drug giant to new heights
Pete Najarian Sees Unusual Options Activity In Advanced Micro Devices And Pfizer
On CNBC's
ASX Today: Record close in the US signals gains ahead
Why Pfizer Shot 4% Higher Today
New York City introduces a sweeping vaccination mandate, as authorities struggle to keep the coronavirus at bay.
What the ETF? Investors look for ASX ETFs with access to cybersecurity and COVID-19 vaccines
Topping the ASX ETF market in July was one of the few cybersecurity-focused ETFs in BetaShares' Global Cybersecurity ETF (ASX:HACK).
U.S. administers 347.4 million doses of COVID-19 vaccines
U.S. administers 347.4 million doses of COVID-19 vaccines – CDC
Top Penny Stocks to Buy? Why These 3 Should Be on Your Watchlist
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
These elements may represent billions of dollars in the months and years to come.
U.S. donates more than 110 million COVID-19 vaccine doses abroad -White House By Reuters
U.S. donates more than 110 million COVID-19 vaccine doses abroad -White House
Sanofi to buy mRNA developer for $3.2 billion
Shares of Translate Bio Inc. undefined soared 29.8% in premarket trading on Tuesday after Sanofi undefinedundefined said it will spend $3.2 billion to buy…
How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks
It'll push the winners further ahead of the laggards.
What to know: Delta variant and Covid shots
“Authorised vaccines effectively prevent serious illness and hospitalization, research shows,” writes The Wall Street Journal.
Global Meibomian Gland Dysfunction Treatment Market Size to Grow at a CAGR of 9.2% from 2021 to 2030
The Global Meibomian Gland Dysfunction Treatment Market has been estimated to reach a value of USD 158.6 billion in 2021 and is projected to grow at a CAGR…
Global Meibomian Gland Dysfunction Treatment Market Size to Grow at a CAGR of 9.2% from 2021 to 2030
The Global Meibomian Gland Dysfunction Treatment Market has been estimated to reach a value of USD 158.6 billion in 2021 and is projected to grow at a CAGR…